Ignite Creation Date:
2025-12-24 @ 2:48 PM
Ignite Modification Date:
2025-12-25 @ 11:51 PM
Study NCT ID:
NCT04476459
Status:
UNKNOWN
Last Update Posted:
2021-03-15
First Post:
2020-07-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
Sponsor:
Huiqiang Huang
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-07-23
Start Date Type:
ACTUAL
Primary Completion Date:
2022-08-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-08-01
Completion Date Type:
ESTIMATED
First Submit Date:
2020-07-15
First Submit QC Date:
None
Study First Post Date:
2020-07-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-03-10
Last Update Post Date:
2021-03-15
Last Update Post Date Type:
ACTUAL